.... Still, there’s no harm in Walmsley addressing the “perennial question”, as she called it, in her first month in charge. Like Witty, she argued that reliable cashflow
s from vaccines and consumer products are a natural counterweight to the higher risk and more volatile business of developing pharmaceutical drugs. ...
[Read full article on Guardian
Wednesday 26th of April 2017 06:37:04 PM